Opdivo

News

BMS claims first EU okay for adjuvant oesophageal cancer imm...

Bristol-Myers Squibb is in a battle with Merck & Co for position in the upper gastrointestinal cancer immunotherapy market, and has just reinforced its position with an EU approval in t

News

BMS pulls speedy Opdivo approval for liver cancer in US

Bristol-Myers Squibb has withdrawn its US marketing approval for PD-1 inhibitor Opdivo as a second-line, single-agent treatment for hepatocellular carcinoma, a common form of liver cancer,

News

Keytruda beats Opdivo to first-line oesophageal cancer OK in...

Merck & Co's Keytruda has become the first cancer immunotherapy to be approved as a first-line oesophageal cancer therapy in the EU, ahead of Bristol-Myers Squibb's rival Opdivo, but BM

News

Keytruda should lose stomach cancer indication, says ODAC

The FDA's Oncologic Drugs Advisory Committee (ODAC) has voted to strip Merck & Co's Keytruda of its accelerated approval in gastric and gastroesophageal junction (GEJ) cancer, despite a

News

Merck gets a leg-up for Keytruda in first-line kidney cancer

New phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the increasingly competitive first-line kidney cancer market.

News

Heat Bio’s shares ignite on Opdivo combination data in NSCLC

The pairing of Heat Biologics’ lead drug HS-110 with Bristol-Myers Squibb’s blockbuster checkpoint inhibitor Opdivo has boosted survival in patients with non-small cell lung cancer (NSCLC),

BMS claims first EU okay for adjuvant oesophageal cancer imm...

BMS pulls speedy Opdivo approval for liver cancer in US

Keytruda beats Opdivo to first-line oesophageal cancer OK in...

Keytruda should lose stomach cancer indication, says ODAC

Merck gets a leg-up for Keytruda in first-line kidney cancer

Heat Bio’s shares ignite on Opdivo combination data in NSCLC

Setback for MSD as German court blocks Keytruda SC launch

How to meet your physicians where they are online

Opdivo

Editor's Picks